Solid Biosciences Inc. (SLDB)

Solid Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	0	0	8.09	13.62	0	0
Revenue Growth (YoY)	-	-	-40.57%	-	-	-
Gross Profit	0	0	8.09	13.62	0	0
Selling, General & Admin	28.34	27.75	28.95	27.14	21.58	24.58
Research & Development	70.81	76.56	78.42	58.74	64.88	94.74
Other Operating Expenses	-0.06	-0.06	7.18	0	1.94	0
Operating Expenses	99.08	104.25	114.55	85.87	88.41	119.32
Operating Income	-99.08	-104.25	-106.45	-72.25	-88.41	-119.32
Interest Expense / Income	0.1	0	0	0	0	0
Other Expense / Income	-8.93	-8.24	-20.47	-0.07	-0.12	-2.1
Pretax Income	-90.25	-96.02	-85.98	-72.19	-88.29	-117.22
Net Income	-90.25	-96.02	-85.98	-72.19	-88.29	-117.22
Shares Outstanding (Basic)	38	20	9	7	3	3
Shares Outstanding (Diluted)	38	20	9	7	3	3
Shares Change	94.99%	133.60%	19.58%	105.58%	28.91%	21.12%
EPS (Basic)	-3.94	-4.83	-10.10	-10.14	-25.50	-43.65
EPS (Diluted)	-3.94	-4.83	-10.10	-10.14	-25.50	-43.65
Free Cash Flow	-92.54	-95.7	-100.39	-79.05	-57.5	-97.1
Free Cash Flow Per Share	-2.42	-4.81	-11.79	-11.11	-16.61	-36.15
Gross Margin	-	-	100.00%	100.00%	-	-
Operating Margin	-	-	-1315.20%	-530.50%	-	-
Profit Margin	-	-	-1062.28%	-530.01%	-	-
Free Cash Flow Margin	-	-	-1240.33%	-580.36%	-	-
EBITDA	-88.32	-93.43	-83.57	-69.22	-84.37	-114.4
EBITDA Margin	-	-	-1032.53%	-508.25%	-	-
Depreciation & Amortization	1.83	2.58	2.41	2.96	3.92	2.82
EBIT	-90.15	-96.02	-85.98	-72.19	-88.29	-117.22
EBIT Margin	-	-	-1062.28%	-530.01%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).